Download - Trial profile
Macrovascular morbidity at study entry and associated medications
John A Dormandy et al. Lancet 2005;366:1279-89
Kaplan-Meier curve of time to main secondary endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Numbers of first events contributing to the primary composite and main secondary endpoints
John A Dormandy et al. Lancet 2005;366:1279-89
Effect of pioglitazone and placebo on each component of the primary endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Hazard associated with relevant baseline characteristics for the main secondary
endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Change in proportion of patients using concomitant medications
John A Dormandy et al. Lancet 2005;366:1279-89
Change in laboratory data from baseline to final visit
John A Dormandy et al. Lancet 2005;366:1279-89